At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 90 enrolled
Drug / intervention
NW-3509A +1 moredrug
Likely dose
NW-3509A 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIA, Prospective, Randomized, Double-blind, Multiple-dose Study of NW-3509A in Chronic Schizoprhenia Patients Not Responding to Their Current Anti-psychotic Medication
In Brief
A Phase 2 clinical trial evaluating NW-3509A and Placebo for Chronic Schizophrenia. Completed, enrolled 90 participants across 5 sites in 2 countries.
Detailed Summary
A 4-week Phase IIa study to evaluate the safety and tolerability and efficacy of NW-3509A in patients with chronic schizophrenia that are not responding adequately to their current antipsychotic medication (aripiprazole or risperidone). NW-3509A is given as an oral dose range of 15 to 25 mg, BID in a 1:1 ratio.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Schizophrenia
CountriesIndia, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartDec 2015
First PostedDec 2015
Primary CompletionDec 2016
Study CompletionJan 2017
TodayJul 2026
First PostedDec 8, 2015
Enrollment StartDec 1, 2015
Primary CompletionDec 1, 2016
Study CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 10.6 years ago
Interventions
NW-3509Adrug
Patients will be given oral doses of 15, 20 and 25 mg BID of NW-3509A
Placebodrug
Patients will be given oral dose of matching Placebo